Compare BGR & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGR | KMDA |
|---|---|---|
| Founded | 2004 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 443.7M | 460.3M |
| IPO Year | N/A | 2013 |
| Metric | BGR | KMDA |
|---|---|---|
| Price | $17.15 | $8.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 91.2K | ★ 140.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 6.02% | 3.08% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.94 |
| Revenue Next Year | N/A | $9.84 |
| P/E Ratio | $24.71 | ★ $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.92 | $6.50 |
| 52 Week High | $17.92 | $9.35 |
| Indicator | BGR | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 62.94 |
| Support Level | N/A | $7.91 |
| Resistance Level | N/A | $8.88 |
| Average True Range (ATR) | 0.00 | 0.20 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 85.85 |
BlackRock Energy & Resources Trust is a closed-end equity fund providing total return through a combination of current income, gains, and capital appreciation by investing in equity securities and derivatives of energy and natural resources companies. The fund invests in various sectors such as information technology, financials, healthcare, consumer discretionary, industrial, energy, materials, utilities, and others.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.